
usd feb pm et
summari diversifi health care product compani focus nutrit product
diagnost gener drug medic devic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
expect sale grow
organ exceed organ growth
achiev abt sale growth
continu driven medic devic
diagnost busi featur
innov product alin
diagnost system mitraclip
see sale growth compris devic
sale grow high-singl digit core
diagnost mid- high-singl digit rapid
diagnost low- mid-singl digit
pharmaceut mid- high-singl digit
nutrit low- mid-singl digit
continu see emerg market
china brazil long-term growth driver
well-posit benefit
growth health care spend
market market made
revenu howev
expect foreign exchang exposur
neg impact sale
late januari manag
appear inclin make
acquisit expect capit alloc
like focus continu debt paydown
invest organ opportun
think share trade
forward earn well posit
outperform medic devic peer
breadth innov offer
addit robust cash flow
size organ allow
better endur econom slowdown
price pressur result
continu consolid health care player
particularli hospit favor
long-term view exposur
high-growth therapeut area
diagnost
risk target price recommend
weak execut new product launch
delay commerci key
target base
above-p ep
estim continu
expect achiev above-market organ
sale growth double-digit earn growth
forward multipl high-end
five-year rang
risk assess reflect abbott oper
competit market exposur rise price
pressur global market howev compani
rel strong posit key health care product
categori prospect brighten on-going
launch new medic product expans
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview oper four report segment establish
pharmaceut product brand gener diagnost product nutrit product
cardiovascular neuromodul product combin segment gener billion sale
dec come establish pharmaceut diagnost
nutrit medic devic primarili compris cardiovascular
neuromodul product divers oper larg result strateg acquisit made
year well intern research develop program abbott command
lead market posit mani product sell
establish pharmaceut segment product includ broad line brand gener
pharmaceut manufactur world-wide market sold outsid unit state emerg
market product gener sold directli wholesal distributor govern agenc
health care facil pharmaci independ retail abbott-own distribut center
public warehous depend market serv growth strategi busi
increas breadth product offer launch new improv formul regist
product across multipl geograph region competit segment gener health
care pharmaceut compani
diagnost product includ broad line diagnost system test manufactur market
sold world-wide princip product segment includ molecular diagnost system point care
system rapid diagnost system informat autom solut use laboratori core
laboratori system area immunoassay clinic chemistri hematolog transfus
next-gener famili core laboratori system brand alin product segment
subject competit technolog innov price conveni use servic instrument warranti
provis product perform laboratori effici long-term suppli contract product potenti
overal cost-effect product gain
nutrit product includ broad line pediatr adult nutrit product manufactur
market sold world-wide product includ variou form prepar infant formula
similac adult pediatr nutrit product ensur nutrit product use enter
feed jeviti nutrit brand zone perfect bar competit factor
price retail distribut avail product form signific aspect competit search
ingredi innov
cardiovascular neuromodul product includ broad line rhythm manag
electrophysiolog heart failur vascular structur heart devic treatment cardiovascular
diseas well neuromodul devic manag chronic pain movement
disord product segment subject competit technolog innov price
conveni use servic product perform long-term suppli contract product potenti
overal cost-effect product gain
also product blood glucos continu glucos monitor system
includ freestyl brand
impact major develop make major acquisit make sens
complet two major acquisit also anticip make major
acquisit believ compani plenti organ growth opportun invest
two major acquist aler lead firm point-of-car diagnost octob
billion cash st jude medic stj leader cardiac neuromodul
devic januari billion total believ combin stj enabl
becom leader cardiovascular care
also complet sale abbott medic optic vision care busi johnson
johnson billion februari complet sale non-u develop market
specialti brand gener busi mylan nv billion
financi trend revenu grew year-over-year billion dec
compar oper basi sale increas acceler achiev
spent billion revenu research develop compar
billion revenu billion revenu normal ep
growth acceler free cash flow determin cash flow
oper less capit expenditur increas billion nine month end septemb
billion prior-year period
senior vice-president financ
chairman board
execut vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
industri
possibl threat state health
care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
take control hous
repres think see
significantli lower level effort
republican trump administr
tri repeal
hospit spend larg driver medic
equip sale robust
strong economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index rose vs declin
fundament outlook health care
equip sub-industri next month
neutral slightli posit continu
expect compani sub-industri
grow posit macro environ
compani gener benefit
laxer food drug administr fda
technolog advanc sub-industri
also mani product area
equip use non-elect procedur
howev valuat high industri
investor sentiment medic devic
compani appear shaken
volatil late think
higher valuat sub-industri
mostli warrant recent expand
margin robust revenu growth weaker
constant currenc basi expect
revenu sub-industri continu
rise high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess headwind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
tariff billion medic
technolog export septemb
although chines
govern seek lower health care cost
equip manufactur insul
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra rais opinion share abbott laboratori
buy hold rais target
peer ep estim set
ep vs ahead estim sale aid
acquisit rose encourag broad-bas product
geograph growth medic devic establish pharmaceut
diagnost nutrit rebound grew pediatr
nutrit sale grew china follow soft regulatori chang believ
well posit continu broad-bas growth /jeffrey loo cfa
rais target line peer
forward ep estim ep vs
line estim rais ep estim
sale aid st jude acquisit rose oper basi
nutrit sale rose oversea sale rose rebound
recent declin china sale improv sequenti diagnost sale rose
rose encourag broad-bas
see acceler diagnost follow aler deal /jeffrey loo
analyst research note compani news
et cfra maintain buy opinion share
rais target price reflect
above-p multipl ep estim
continu expect exposur high-growth therapeut area drive
above-market organ sale double-digit earn growth ep
vs lower estim lower ep estim
initi ep sale increas
organ billion organ basi sale grew
nutrit busi diagnost establish
pharmaceut medic devic manag
current see compel opportun especi sinc
plenti organ growth opportun manag also note growth
expect depend key approv mitraclip freestyl
libr product see potenti share upsid /kevin huang
et cfra reiter buy opinion share abbott
laboratori rais target
above-p ep estim
formid pipelin drive above-market organ sale growth
come sever year ep vs lower
estim lower ep sale increas
organ billion organ basi sale increas
nutrit busi diagnost establish
pharmaceut medic devic sale diabet care
busi part medic devic increas organ driven
rapid uptak freestyl libr octob obtain ce
mark freestyl libr system next-gener continu glucos
monitor real-tim alarm anoth promis opportun
minimally-invas heart valv repair devic mitraclip recent
posit clinic result coapt studi /kevin huang cfa
laboratori rais target
above-p ep estim
robust organ growth opportun driven compani pipelin
ep vs higher estim rais
ep ep sale increas
organ billion organ basi sale grew
nutrit busi diagnost establish
pharmaceut medic devic given stronger-than-expect
organ growth quarter increas expect organ sale
growth rang year recent launch
freestyl libr continu glucos monitor maintain rapid pace growth
user per month achiev total user global
promis product includ alin diagnost system
mitraclip valv repair /kevin huang cfa
keep target above-p
next ep estim due robust pipelin
ep estim remain unchang respect
ep vs ep higher estim
pharmaceut medic devic total sale grew organ
line expect organ growth
diabet care busi grew driven recent
launch freestyl libr user global monthli growth
diabet care could import growth driver year come
addit cadenc new product launch continu invest
research develop million vs
persuad us continu see organ growth exce
growth experienc recent year /kevin huang
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
